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which it leads, the impact of COPD on relatives and caregiv-
ers, the limitation of daily life observed in these patients, and 
the economic and societal burden that they represent for the 
health system, are not so well-known. A major problem is the 
high under-diagnosis, mainly due to difficulties for obtaining, 
in a systematic way, spirometries in hospitals and health-care 
centers. For this reason, the Fundación de Ciencias de la Salud 
and the Spanish National Network Center for Research in Res-
piratory Diseases (CIBERES) have brought together experts in 
COPD, patients and their organizations, clinical psychologists, 
experts in health economics, nurses and journalists to obtain 
their opinion about COPD in Spain. They also discussed the sci-
entific bibliometrics on COPD that is being carried out from 
the CIBERES and speculated on the future of this condition. 
The format of the meeting consisted in the discussion of a se-
ries of questions that were addressed by different speakers and 
discussed until a consensus conclusion was reached.
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ABSTRACT
Chronic obstructive pulmonary disease (COPD) is one 
of the most prevalent diseases in the World, and one of the 
most important causes of mortality and morbidity. In adults 
40 years and older, it affects more than 10% of the popula-
tion and has enormous personal, family and social burden. To-
bacco smoking is its main cause, but not the only one, and 
there is probably a genetic predisposition that increases the 
risk in some patients. The paradigm of this disease is changing 
in Spain, with an increase of women that has occurred in re-
cent years. Many of the physiopathological mechanisms of this 
condition are well known, but the psychological alterations to 
Correspondence:
Emilio Bouza MD, PhD 
Instituto de Investigación Sanitaria Gregorio Marañón 
C/ Dr. Esquerdo, 46 - 28007 Madrid, Spain
Phone: +34- 91- 586 84 53/Fax: +34- 91- 504 49 06 
E-mail: emilio.bouza@gmail.com
Esteban Palomo, PhD
Director. Fundación de Ciencias de la Salud.
C/ Severo Ochoa, 2, - 28760 Tres Cantos. Madrid
Phone +34 91 3530150
Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a 
multidisciplinary opinion document  
E. Bouza, et al.
Rev Esp Quimioter 2020;33(1): 49-67 50
For all the above-mentioned reasons, the Fundación de 
Ciencias de la Salud and the Spanish National Network Center 
for Research in Respiratory Diseases (CIBERES) organized a 
meeting, about COPD in Spain, bringing together experts from 
very different areas, as well as patients and their associations. 
We aimed to discuss, not only the clinical manifestation or the 
treatment of the disease, but mainly the impact in patients’ 
daily life, in their caregivers, and in other related areas such as: 
the economy, the non-specialized press, and the health-care 
system organization.
All participants received a series of questions about COPD, 
which the coordinators felt needed an answer based on ev-
idence, otherwise also on opinion. Each one of the speakers 
presented one of the questions, providing the information that 
allowed, after a discussion among all the members of the pan-
el, to reach a response agreed upon by all.
As a disclaimer, all panel members participated, in their 
personal capacity, and the opinions they expressed do not nec-
essarily represent those of their working groups or institutions.
This document is not intended to provide recommenda-
tions or therapeutic guidelines, but simply to help to establish 
a debate, and present an abridged collection of approaches 
and opinions of participants.
The meeting took place in Barcelona on October 31st, 
2018, and this document tries to summarize the main issues 
discussed, the documentation provided on them and the con-
clusions that were agreed upon by the group. The final docu-
ment has been approved by all participants, and it represents 
the group’s opinion. 
MATERIAL AND METHODS
Questions were chosen by the coordinators and agreed 
upon by all speakers. They were classified in three main groups 
of issues: the situation of the problem in Spain; its social and 
economic dimension; and the possibilities of effective im-
provement.
The document, edited in a first draft, was sent to all 
co-authors for their corrections and amendments. The final 
document has been reviewed and approved by all authors.
Next, we will review the questions posed, the arguments 
provided, and the conclusion reached by topic.
Question 1. What is the dimension of the COPD prob-
lem in Spain?
Text:
COPD is an important cause of morbidity and mortality 
in Spain, with a high health, economic and social impact. It 
is now widely recognized that COPD is a heterogeneous and 
complex syndrome, with pulmonary and extrapulmonary in-
volvement [1]. In usual clinical practice, the diagnosis of COPD 
is based on the evaluation of exposure to tobacco smoke or 
other harmful fumes and gases, the presence of persistent res-
Enfermedad Pulmonar Obstructiva Crónica 
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RESUMEN
La enfermedad pulmonar obstructiva crónica (EPOC) es una 
de las enfermedades más prevalentes en el mundo y una de las 
causas más importantes de mortalidad y morbilidad. En los adul-
tos de más de 40 años, afecta al menos al 10% de la población y 
tiene una enorme carga personal, familiar y social. El tabaquismo 
es su principal causa, pero no la única, y probablemente existe 
una predisposición genética que aumenta el riesgo en algunos 
pacientes. El paradigma de esta enfermedad está cambiando 
en España, con un aumento de la incidencia en mujeres que se 
ha producido en los últimos años. Muchos de los mecanismos 
fisiopatológicos de la EPOC son bien conocidos, pero no lo son 
tanto las alteraciones psicológicas a las que conduce, el impacto 
de la enfermedad en los familiares y cuidadores, la limitación de 
la vida cotidiana que se observa en estos pacientes y la carga 
económica y social que representan para el sistema sanitario. 
Un problema importante es el elevado infra-diagnóstico, debido 
principalmente a las dificultades para obtener, de forma siste-
mática, espirometrías en los hospitales y centros de salud. Por 
este motivo, la Fundación de Ciencias de la Salud y el Centro 
de Investigación en Enfermedades Respiratorias (CIBERES) han 
reunido a expertos en EPOC, pacientes y sus organizaciones, 
psicólogos clínicos, expertos en economía de la salud, enfermeras 
y periodistas para obtener su opinión sobre la EPOC en España. 
También se ha hablado de la bibliometría científica sobre la EPOC 
que se está llevando a cabo desde el CIBERES y se ha especulado 
sobre el futuro de esta enfermedad. El formato de la reunión 
consistió en la discusión de una serie de cuestiones que fueron 
abordadas por diferentes ponentes y discutidas hasta llegar a 
una conclusión consensuada.
Palabras clave: Enfermedad Pulmonar Obstructiva Crónica, Impacto psico-
lógico, Carga de trabajo, Atención sanitaria, Economía de la Salud, Espiro-
metría, Investigación bibliométrica, Organizaciones de pacientes
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of 
the most frequent causes of morbidity and death in the World, 
and in Spain. Chronic inhalation of toxic fumes, particularly 
from tobacco smoke, is the most common causal risk factor, 
but not the only one. COPD usually appears in its most severe 
and symptomatic forms after the age of 65, considerably di-
minishing quality of life and the possibility of having an inde-
pendent, autonomous life.
The available scientific information on COPD is vast, par-
ticularly biomedical information on COPD. However, data re-
garding other aspects, such as: the impact in the daily life of 
patients, the experience of care-givers, the economic impact in 
the health-care system and the attention from the mass-com-
munication media to this problem, have received less attention.
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istry of Health, Consumption and Social Welfare of Spain, in 
2017, the prevalence of smokers fell to 22% of the population, 
the lowest figure in the last 30 years. The report also present-
ed important differences between men and women: 25.6% of 
men smoked daily, compared to 18.8% of women. The previ-
ous figure, from the 2011-12 survey, was close to 24%. How-
ever, this decrease is taking place at a slower pace in women 
than in men.
During this meeting, the results of EDADES, the Survey on 
Alcohol and Drugs in Spain, were released. The number of mi-
nors who had smoked in the last year increased from 20.6% in 
2015 to 25.4% in 2017, and globally there was a notable in-
crease in smoking to reach a worrying 34% of adults in 2018, 
which should be monitored.
More resources should be devoted to controlling tobac-
co smoking in the population and, above all, in patients with 
COPD, which could be carried out at different levels: state reg-
ulations, educational interventions, cutting smoking in current 
smokers ... It is well known that a simple, brief advice from a 
health-care professional increases the likelihood of quitting 
smoking. However, the overall success rate of smoking cessa-
tion is low. Consequently, there is an urgent need to demon-
strate the efficacy of all interventional strategies in tobacco 
use, including a report on lung age. It is essential to underline 
the need to treat tobacco addiction (ICD10 F17 disease) as a 
chronic, relapsing disorder. Health professionals have an obli-
gation to emphasize to our political representatives the need 
to promote research into smoking cessation. 
Despite its high prevalence rates, COPD remains a dis-
ease with high rates of under-diagnosis, with percentages 
in Spain of 78% in 1997 and 73% in 2007. This fact leads to 
diagnoses in advanced stages, when there is a greater risk of 
exacerbations and mortality [8]. It is estimated that more than 
1,595,000 Spaniards do not know they suffer from the disease 
and, therefore, do not receive any treatment for their COPD. 
The reasons for this are multiple and complex. The main one is 
the low use of spirometry in the general population and in the 
“at risk” population. There is an association between not hav-
ing a diagnosis of COPD and living in rural areas, being female, 
having a younger age, low socioeconomic level, and absence of 
a previous history of smoking [9].
The global estimates in 2010 indicated that COPD was al-
ready considered the third global cause of mortality [10, 11], 
so an early diagnosis is of vital importance.
In 2017, a new epidemiological study was planned to up-
date the prevalence and determinants of COPD in Spain, with 
representation from all 17 Autonomous Communities (CCAA). 
The aim would be to extend the assessment beyond spirom-
etry, contemplating other dimensions with questionnaires of 
respiratory and non-respiratory symptoms, a broader func-
tional evaluation and, in some cases, biological tests such as 
inflammatory markers, and imaging with low-radiation com-
puted tomography[12].
piratory symptoms (exertional dyspnea, cough with/without 
expectoration) and the identification of a persistent airflow 
limitation, documented by spirometry after a bronchodilator 
test [1, 2].
While direct or indirect exposure to tobacco smoke is 
considered the primary, causal COPD risk factor, other envi-
ronmental exposures (biomass, marijuana and other smoked or 
vaped substances, air pollution, occupational exposures, and 
else) may contribute to its development, as well as individu-
al host factors (gender, genetic abnormalities, abnormal lung 
development, accelerated lung aging, or neonatal respiratory 
infections) may predispose to it [1, 2]. 
COPD screening should be considered in any person over 
the age of 50 with dyspnea and/or cough as well as exposure 
to risk factors, tobacco smoking being the most relevant [3]. 
The EPISCAN study, carried out in 2007, reported a preva-
lence of 10.2% of COPD in the general Spanish population 40 
to 80 years old, with great variability among the participat-
ing centers [4]. Other studies such as PLATINO estimated even 
higher prevalence, 14.3%, in Latin American capitals over 40 
years of age [5, 6]. Previously, IBERPOC estimated that in Spain 
1,228,000 people between 40 and 69 years old suffered from 
COPD [7].
Variations in COPD prevalence are largely a reflection of 
cumulative exposure to tobacco smoke. During the last dec-
ade, health policies have changed, with the entry into force of 
the Anti-smoking Law 28/2005 of 2006 and the subsequent 
amendment of 2011 by Law 42/2010. On the one hand, it is 
sensible to think that these health interventions of primary 
prevention could contribute to a decrease in the prevalence of 
COPD, since tobacco in Spain continues being the main cause 
of COPD. On the other hand, since the first EPISCAN study, 
forms of smokeless tobacco such as electronic cigarettes have 
appeared, and it will be of interest to assess the impact that 
this type of device has had on the smoking of the population 
and on the development of COPD and other respiratory con-
ditions.
Conclusion:
The prevalence of COPD in Spain is high and is esti-
mated to affect more than 10% of the adult population. 
The geographical variation is wide, and the most impor-
tant and consistent risk factor is tobacco smoke.
Question 2. Is there a significant COPD underdiagno-
sis? Of what magnitude? For what reasons? 
Text:
It is well established that tobacco smoking is the first 
cause and the most important risk factor for developing COPD 
in Spain. In patients who continue smoking, lung function de-
creases more rapidly than in those who quit. At any rate, the 
frequency of tobacco use remains high, and a high proportion 
of patients with COPD (close to 40%) continue smoking de-
spite suffering symptoms of the condition [3]. 
According to the National Health Survey 2017 of the Min-
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of Community Nursing and Primary Care (FAECAP). This 
training must be completed with adequate recycling and 
maintenance of skills, through regular courses or work-
shops [18, 24].
Despite certain articles [25-27] of national scope, 
where an enormous variability between different au-
tonomous communities is identified, and the low adap-
tation to the quality criteria established by the national 
regulations on spirometries, there is a clear example that 
Primary Care spirometry is possible, which is the Balear-
ics Program of Spirometry in Primary Care. There, after a 
comprehensive training in spirometry, a significant im-
provement has been achieved since its implementation in 
both process and result aspects, with an increase in the 
number of spirometries in all centers, in the proportion of 
patients diagnosed with asthma and COPD with spirome-
try, and in the proportion of quality spirometries.
Conclusion:
Spirometry is a technique that should be performed 
in Primary Care by properly trained nurses, through 
courses currently available in both national and interna-
tional scientific societies. There is a great interregional 
variability in the performance of spirometries in Primary 
Care in Spain, being the Balearics Program one of those 
that has accredited and demonstrated better results.
Question 4.- What is the burden of work-related and 
personal disability due to COPD?
Text:
There is no available macroeconomic data in Spain on the 
distribution of sick-leaves due to COPD [28]. In a recent re-
port, pooling data on temporary work disability in Catalonia 
between 2010-15, the main cause was respiratory conditions, 
which caused 21% of them, excluding those due to infections 
or tumors [29].
COPD costs can be divided into direct costs (drugs, 
tests, hospital admissions, consultations, etc.) and indi-
rect costs (permanent disability, sick leave, career-related, 
etc.), the latter being always more difficult to measure. 
It is estimated that 60% of the expenses generated by 
COPD are attributable to indirect costs [30].
Another relevant point for estimating work-relat-
ed costs of COPD is the percentage of COPD patients of 
working age. In studies based on surveys, this percentage 
ranges from 23 to 36%, increasing in prevalence studies 
to 45% (30-32).[30-32]
In two Spanish studies, between 8 and 13 % of pa-
tients with COPD in active employment had had sick 
leave in the last year [32, 33]. In another study, pub-
lished in 2018, on 3,627,107 episodes and 237,219,230 
days of temporary incapacity in Catalonia between 2007 
and 2016, 3% were considered to be due to tobacco, of 
which 66% of the episodes and 23% of the days on sick-
leave were attributable to respiratory causes [29]. 
Conclusion:
The underdiagnosis of COPD is a generalized and 
universal fact. In Spain it is estimated that it exceeds 
70% of cases and the reasons most frequently related to 
under-diagnosis are limited use of spirometry in the pop-
ulation at-risk, residence in rural areas, female gender, 
having a low socioeconomic level, and absence of a previ-
ous history of smoking.
Question 3. How to address the implementation of 
spirometry in Primary Care?
Text:
Spirometry is a diagnostic tool that should be widely 
performed in Primary Care, since it is there where patients 
with respiratory diseases, such as COPD and asthma, are 
most frequently detected: They will benefit from an early 
diagnosis that will allow both preventive and therapeutic 
measures to be taken to avoid their progression [13].
To make this possible, it is essential to train both the 
medical and nursing staff who should perform the test. 
This training should be regulated and include all the fol-
lowing [14-17]:
- Basic knowledge of pulmonary physiology. 
- Indications and contraindications of the test.
- Knowledge of the measures necessary to achieve cor-
rect maneuvers.
- Recognize technical errors and know how to avoid 
them.
- Evaluation of the curves made, and selection of the 
most suitable according to acceptability and repro-
ducibility criteria.
- Knowledge to interpret spirometric patterns.
- Ability to evaluate the patient’s physical or intellectu-
al circumstances that modify the technical require-
ments of the maneuver, such as patients in wheel-
chairs, mental problems, etc.
This technique should be known by all nursing staff 
and must be integrated with the rest of the techniques 
performed daily, to minimize waiting times. It would be 
advisable to avoid delays between the prescription and its 
performance, overall one week or shorter.
Training, in most countries, is carried out by means 
of accredited courses and workshops [18-20], lasting be-
tween 5 and 12 hours, which enable this technique to be 
carried out adequately in the health center, where most 
of the time only forced spirometries are carried out with 
a computerized spirometer. There are international [21] 
and national initiatives for the accreditation of “spiro-
metrists”, such as the “Spirometry Driving License” of the 
European Respiratory Society, [22] or the Training Course 
in Spirometry of the Spanish Society of Family and Com-
munity Medicine, [23] and the Federation of Associations 
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various treatments for COPD. If we use the most recent study, 
we can calculate an overall COPD cost of 36.2 million Euros 
for Extremadura in 2015, which extrapolated to the remaining 
Spanish population adds up to a COPD global cost in Spain of 
1,547 million Euros in 2015.
COPD costs in Spain are significantly lower than those ob-
served in surrounding countries, due to the lower costs asso-
ciated with health care in our country. Thus, in Germany, the 
average annual cost of a patient with COPD is 7,263 euros [39], 
and in Greece it has been calculated at 4,730 euros [40]. Of 
course, in North American countries the cost is significantly 
higher: in Canada, where it reaches an average of 8,600 Ca-
nadian dollars [41]. Again, these costs do not reflect differenc-
es in prevalence, severity or prognosis, but rather the lowest 
manpower cost in Spain.
Given these figures, we must ask ourselves: what is being 
done to prevent COPD? Likely, the answer is that there is no 
direct investment in preventing the COPD epidemic. The best 
option is prevention of smoking, and restrictive legislative 
measures have been a great step forward, which should trans-
late into a reduction in the costs of COPD in the decades to 
come. Other alternatives are the prevention of exacerbations, 
and reductions in the progression of the disease with appro-
priate treatment, physical activity, and vaccination, among 
other interventions.
Conclusion:
Estimates based on data from Extremadura (Spain), 
conclude that approximately € 3,000 per patient is the 
average annual cost of a patient with COPD in Spain. This 
adds up to an estimate of 1,547 million Euros cost in 
2015 in Spain.
Question 6.- What are the main preventive measures 
for COPD? What is their effectiveness?
Text:
COPD is caused primarily by inhalation of tobacco smoke 
and, to a much lesser extent, by inhalation of biomass smoke, 
a more frequent cause in developing countries. Tobacco use 
is particularly relevant in respiratory medicine, as it is also 
the leading cause of lung cancer. Tobacco use is a predispos-
ing factor for respiratory infections including pneumococcal 
pneumonia, influenza and tuberculosis. People with the least 
education, those with the least purchasing power, those be-
tween the ages of 18 and 24, and those working in construc-
tion are the most likely smokers. There are currently more than 
one billion smokers in the world. Active and passive smoking is 
responsible for more than 6.3 million deaths annually, which 
represents 6.3% of the total burden of disease. The WHO goals 
are focused on reducing the demand and sale of tobacco in 
the world through educational strategies, policies and legis-
lation [42].
Tobacco smoke contains an aerosol of particles including 
water, nicotine and thousands of chemical substances that are 
harmful to the human organism, by absorption of toxins and 
Extrapolating the previous data to the national set, we 
can calculate that in Spain there are about 3,000,000 patients 
with COPD, and among them there would be between 100,000 
and 150,000 lost work days per year. 
As for permanent disability, it has been estimated that 5 
to 10% of all permanent disabilities in Spain are due to COPD 
[32-34]. The cost per patient of permanent, early retirement 
has been estimated at 5,645 euros per patient [35, 36]. To this 
amount, the cost of the caregiver should be added, plus nurs-
ing homes and those due to COPD comorbidities.
The calculation of Disability-Adjusted Life Years (DALY`s) 
is a way of quantifying the burden of an illness, by taking into 
account years of life lost plus years of life lived with disabili-
ty. A DALY can be considered as a health-weighed lost year of 
life. Data from Spain corresponding to 2016 show that COPD 
caused a total of 654.4 x 100,000 (610.9-705.7) DALYs, being 
the 7th cause in the overall ranking of causes of DALYs, that is 
contributing to 2.8% of the total DALYs. The number of DALYs 
due to COPD is highly variable, depending on age and sex, in-
creasing more than 10 times in men over 80 years up to values 
of 8,274 x 100,000 (7,417-9,259). In this age group, COPD rep-
resents the 3rd position in the overall ranking of DALYs, just 
behind ischemic heart and Alzheimer’s disease.
Conclusion:
In Spain, COPD generates between 5% and 10% of 
all permanent sick-leaves. Globally, COPD is attribut-
ed with 650 DALYs per 100,000 inhabitants, although 
in men over 80 years this rate increases up to to 8,274 
DALYs per 100,000. 
Question 5.- How much does COPD costs to society? 
How does Spain compare with countries of similar level 
of development in this aspect?
Text:
It has been already mentioned, 10.2% of individuals aged 
40 to 80 years old in Spain have COPD, [4] and this trend is ex-
pected to increase, due to population ageing. In a large study 
carried out more than a decade ago in the USA, the average 
direct annual cost of COPD was calculated at 1,876 USD per 
patient, although this cost depended on the severity of the pa-
tient (from 1,484 to 2,911 USD). Of this expenditure, 43.8% 
corresponded to hospital expenditures, 40.8% to drugs, and 
15.4% was due to diagnostic tests and medical visits [37].
A very recent study in Extremadura, calculated an average 
annual expenditure per patient with COPD of 3,077 Euros, with 
a distribution that attributes 43.8% to direct health expend-
iture (1,645 Euros), 38.3% (1,440 Euros) to direct non-health 
expenditure (non-health centers, caregivers, etc.) and 17.9% 
(672 Euros) to productivity losses[38].
It is worth noting that, despite the increase in drug prices 
for COPD, costs have remained very stable, between 1,876 USD 
and 1,645 Euros/patient/year in both studies almost 15 years 
apart. It is likely that the higher cost of drugs is been offset by 
a decrease in hospital costs, due to a greater effectiveness of 
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ability, less cognitive deterioration, and even less brain atrophy 
measured by magnetic resonance (physiologically the brain 
size decreases with age)[46]. Data from the “Global Burden of 
Disease Study” show that between 1990 and 2013, years lived 
without disability had increased in a manner similar to life ex-
pectancy [47].
When exploring old age and COPD, the first problem that 
arises is that in elderly patient’s COPD is more difficult to diag-
nose, given the presence of comorbidities that can mimic simi-
lar symptoms (e.g. heart failure), or limit exercise capacity (e.g. 
peripheral vascular disease). In addition, patients sometimes 
mistakenly attribute dyspnea to a natural process associated 
with aging. Spirometric confirmation is also more difficult in 
the elderly, since 25% of them cannot perform quality spirom-
etry, and the time required for its performance is longer. In 
this sense, devices that use the FEV1/FEV6 ratio may be useful, 
since the greatest difficulty in the elderly population is com-
pleting forced exhalation [48, 49]. 
Elderly people hospitalized for a COPD exacerbation have 
less spirometric severity, but more symptoms and more co-
morbidities [50]. Another important issue is the difficulty in 
correctly using inhalation devices, due to the impossibility of 
“doing the clamp”, dyspraxia or insufficient inspiratory capac-
ity. It is therefore essential to check its correct use, in many 
cases with the help of the caregiver. And in doubt, it is rec-
ommended to use devices that assure that the inhalation has 
been correct.
In the elderly, frailty is frequent, meant as a diminished 
functional reserve, which in case of presenting a complication 
can lead to disability. It is estimated that a hospitalization due 
to COPD causes a loss of 5% of the strength of the quadri-
ceps, and that the time required to recover the ability to walk 
is greater than in young people [51]. Finally, the presence of 
several comorbidities that interact with each other is frequent 
in elderly persons, making it virtually impossible to identify a 
main condition, so that in many cases the use of the term mul-
timorbidity is preferable to that of comorbidity.
Conclusion:
Ageing and its related accumulation of diseases, 
makes diagnostic confirmation of COPD more difficult, 
because symptoms may be attributable to other diseases. 
Correct performance of spirometry tests is more difficult 
in this population. 
Question 8.- How is a day in the life of a patient with 
advanced COPD? The vision of a patient.
Text:
Life with COPD is complicated. With discipline, will, 
and external help you can aim to having a life like that of a 
healthy person, but not the same. Everything is much slower, 
and therefore everything must be very programmed. Portable 
oxygen therapy allows to make social life outside the home, 
but slowly and programmatically. And at the end of the day, a 
great deal of tiredness accumulates, and you must retire soon.
by local toxicity in the lungs through chemical oxidants. To-
bacco use is the cause of 80% of COPD, either emphysema or 
chronic bronchitis. The mechanisms causing COPD by tobacco 
are complex and include inflammation and direct lung damage 
by oxidative substances, increased elastase activity (proteins 
that act against elastins and connective tissue), and decreased 
antiprotease activity.
The most effective preventive measure against COPD is 
tobacco control and cessation. Of the total number of smok-
ers, 70% acknowledge their intention to quit smoking, and ap-
proximately half try at least once a year. Spontaneously and 
individually, only 1% achieve effective quitting. With simple 
medical advice success reaches 3%. Minimum intervention 
programmes are effective in 5-10% of smokers, while more 
intensive treatments can be successful in 25-30%. Intensive 
treatments are not easy to implement, due to limited resourc-
es, although existing regulations recommend that all smokers 
attempting to quit smoking should have access to anti-tobac-
co drugs. The drugs approved to treat tobacco use are nicotine, 
bupropion and varenicline. In a few studies, all of these drugs 
have been shown to double cessation of tobacco use compared 
to placebo. Concomitant administration of nicotine (long- and 
short-duration) with bupropion or varenicline increases the ef-
fectiveness of the treatment.
The benefits of quitting smoking are evident at any age 
and include: decreased risk of cancer, decreased risk of acute 
myocardial infarction, decreased loss of lung function, and in 
pregnant women, decreased likelihood of giving birth to low 
birth weight infants. In general, patients who quit smoking 
may gain 10 kilos of weight, and this may be a reason for some 
patients not to stop smoking [43, 44].
Conclusion:
The most effective preventive intervention against 
COPD is smoking cessation. Although 70% of smokers 
want to quit, and half try it once a year, only 1% quit 
successfully without any help; 3% achieve this only with 
simple medical advice, 5-10% with minimum interven-
tions, and 25-30% after intensive treatments that in-
clude anti-smoking drugs. 
Question 7.- How do aging and chronic diseases af-
fect the lives of patients with COPD? 
Text:
Life expectancy in most countries has increased in re-
cent years, although ageing is associated with an increase in 
chronic diseases and disability. We are witnessing what Fries 
called the Theory of Compression, as early as 1980 [45]. We 
live longer, but disability and aging are compressed in the last 
years of life. It is tantamount to saying that we age later and 
renders obsolete the classic definition of “old”, applicable to 
anyone over 60 or 65 years of age.
Cohort studies carried out in nonagenarians, 10 years af-
ter their inclusion in the study, show that the nonagenarians 
of the most recent cohorts had longer life expectancy, less dis-
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selves from the general world, from family, and even from 
himself. Sometimes they identify with the oxygen concen-
trator and forgets his philias and phobias. On the other hand, 
patients feel shame and guilt because they understand that 
certain unhealthy life habits, such as smoking, led them to this 
situation. Guilt is one of the most complex emotions to deal 
with, since it is related to “repair”, something barely achievable 
in this situation.
All this, if not addressed from the beginning and as the 
disease progresses, inevitably means the loss of a sense of dig-
nity as a person. Dignity, like demoralization and emotional 
distress (anxious-depressive pictures) configures one of the 
essential needs of the person: spirituality [54]. We understand 
spirituality as an intrapersonal dimension (sense of coherence), 
interpersonal (relationships with others and feeling of peace) 
and transpersonal (legacy, hope). The person with COPD often 
identifies more with the idea of “sick” than with the real idea 
that it is “he/she himself/herself”.
The care of emotions of any person with COPD is the main 
preservative of dignity and, therefore, of quality of life.
Conclusion:
Anxiety and depression are two common manifesta-
tions associated with COPD, conditioned by the loss of 
autonomy and dependence on many activities of daily liv-
ing. The care of emotions, and their management, is the 
main way to preserve dignity and, therefore, quality of 
life.
Question 10.- How does the presence of a COPD pa-
tient impact the family? Vision of the non-professional 
caregiver.
Text:
The caregiver is a fundamental pillar for patients with 
COPD. We will distinguish between health professionals and 
informal caregivers such as friends, family, neighbors, which in 
most cases are those who will provide care at home. This role is 
often underestimated, both in the literature and in many of the 
documents that deal with the disease. We can see how those 
patients who have a caregiver have a better tolerance to exer-
cise, fewer readmissions, and better adherence to treatments, 
than those who live alone [55, 56]. Sometimes the caregiver’s 
vision, especially when dealing with a close relative, is to be car-
ing for a fragile person. This worry with what the patient may 
suffer has negative consequences for the patient due to the 
anxiety and fear that this may cause, leading to overprotection 
of the patient, and making him or her more dependent. Hence 
the importance of the education that health professionals must 
provide, not only to the patient, but also to caregivers.
Dyspnea is the main symptom of any COPD patient. And 
together with fatigue, cough and altered sleep patterns, lim-
its physical activity and activities of daily living [57]. Overall, 
57% of patients who suffer from dyspnea in their severe or 
very severe stages have morning symptoms which will prevent 
The main limitation is mobility. A lot of help is needed for 
many things, especially boarding vehicles, getting into eleva-
tors, etc. All movements must be programmed and knowing in 
advance the accessibility of the places you are going to visit. 
Another important limitation is the provision of oxygen, as the 
backpacks last 4 hours, and then you must go back home to 
recharge. We often stop going to events because of the dif-
ficulty in overcoming unforeseen events, but by planning we 
can do almost anything.
I am asked if the COPD is a stigmatized disease. Personally, 
I do not feel that way, but other patients may feel stigmatized. 
I have been with this disease for a long time, and I consid-
er that the stigma disappears more and more, and that it has 
been diminishing in the last years. One aspect to be comment-
ed from the perspective of a patient is the frequency with 
which COPD patients feel misunderstood and try to “justify” 
their situation. Friends and relatives tend to think that we are 
comfortable, and that we do not do certain things because we 
do not want to.
Conclusion:
The life of a COPD patient with advanced disease is 
limited by the lack of mobility, the need for portable oxy-
gen therapy, and the slowing down of all activities. Activ-
ities of daily living must be highly programmed, unfore-
seen events are mishandled, and the patient often blames 
him/herself, and needs to justify.
Question 9.- How does COPD impact the affective, 
psychological, social, sexual and spiritual spheres of the 
patient? The psychologist’s vision.
Text:
Breathlessness is one of the most frightening experienc-
es of any human being. The suffering that accompanies not 
being able to breathe, or doing so with difficulty, blocks and 
stops any activity [52]. A headache, as long as it is not inca-
pacitating, or a toothache, allow us to continue with certain 
activities, but lack of air does not. There is no need to point 
out the impact this has on people, at all levels. Several studies 
quantify the presence of anxiety and depression in COPD pa-
tients [53]. The consequences of COPD are felt beyond physical 
problems: it is a disease that, because of its main symptom, 
affects the whole person. The emotional impact is undeniable, 
and these emotions vary from day to day. Precisely, being able 
to manage emotions, not blocking them, can make the patient 
manage better or worse, their day to day. 
The patient’s loss of autonomy leads to a feeling of glob-
al dependence and denial. He/she rejects all sorts of activities, 
even the most intimate ones, such as affective or sexual activ-
ities. It accompanies the sensation of failure, discouragement, 
hopelessness and sometimes even loss of meaning in life. This 
is what we would call “demoralization syndrome”, while the 
main difference with depression would be anhedonia; a pa-
tient with depression is unable to enjoy anything.
On the one hand, COPD patients tends to isolate them-
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7.- Review the cleanliness of materials (inhalers, chambers, na-
sal goggles, humidifiers...).
8.- Check food and water intake.
9.- Revise physical activity and respiratory rehabilitation.
10.- Teach energy saving techniques.
11.- Encourage self-care.
12.- Control vaccination schedule.
13.- Program strategies for smoking cessation.
14.- Teach how to recognize and react whenever a COPD exac-
erbation occurs.
15.- Help to program and maintain leisure time.
16.- Help in the programming of trips and vacations.
17.- Serve as a liaison with the Social Worker. 
18.- Development of learning and reinforcement workshops 
for the patient´s caregivers.
19.- Support during the progression and worsening of the dis-
ease, and during the end of life.
Conclusion:
The role of nursing is essential in the care of COPD 
patients. There is a direct responsibility for patient and 
caregiver’s health education, and in the psychosocial sup-
port for both.
Question 12.- Women and COPD. Does COPD choose 
gender or does gender choose COPD? Is COPD different in 
women?
Text:
COPD is characterized by a chronic, progressive and ir-
reversible limitation to airflow associated with exposure to 
tobacco smoke and, to a lesser extent, to occupational and 
environmental inhalants or products derived from biomass 
combustion. In addition to exposure factors, there are other 
host-related factors, such as genetic susceptibility or abnormal 
lung development, that predispose individuals to develop the 
disease [62-64].
In Spain, data from the EPI-SCAN study concluded that 
COPD prevalence reached 10.2% (15.1% in males and 5.7% in 
females) [65] while, ten years later, preliminary results from 
EPI-SCAN II (unpublished) suggest that the prevalence of the 
disease rises, and its increase is more remarkable in females 
(9.5%) than in males (16.9%), with still a high rate of un-
der-diagnosis.
In Spain, ageing of the population, more pronounced in 
women due to their greater longevity, and their massive in-
corporation into tobacco use around the 1970s, has led to an 
increase in respiratory diseases associated with smoking in 
women. The latest National Health Survey, published in 2017, 
indicates that while in men there is an annual decrease in 
smoking (18 percentage points since 1993), in women, there 
has been a phenomenon of maintenance with leveling off, 
However, with alarming trends among the youngest, where 
them from showering or dressing autonomously [58]. This af-
fects family life to the point of having to change habits, to live 
together as a couple, or to stop sharing activities, forcing the 
patient and the family to implement strategies to minimize the 
consequences of these symptoms. In patients of working age, 
these limitations may imply a change or interruption of their 
professional activity, with the socioeconomic consequences 
that this entails.
The caregiver is often responsible for medication and 
symptom management, will provide assistance in activities of 
daily living, and will provide physical and emotional support 
to the patient. This increased workload will affect the patient’s 
social and working life, and the caregiver may experience anxi-
ety, worry, fear for the future, loss of autonomy and social life, 
and finally depression. These symptoms tend to increase as the 
disease progresses. In the final stages of COPD, the fear that 
the patient may die with suffering becomes a cause of great-
er emotional stress. Caregivers often complain that the infor-
mation, emotional treatment or support they have at home is 
insufficient [59]. Yet they are forced to constantly adjust their 
role, with reconsideration of their needs.
But caring can also be positive and rewarding and teach-
ing the caregiver how strong he or she can become is essential 
[60]. Hence the importance for health professionals to care for 
and accompany the caregiver during this journey, and later in 
the process of adjusting to the loss of care during the bereave-
ment phase [61].
Conclusion:
COPD patients with caregivers have better exercise 
tolerance, fewer readmissions, and better adherence to 
treatments than those without caregivers. Caring for, 
teaching and supporting the caregiver on their endeavors 
is an essential responsibility of health-care workers
Question 11.- What is the role of nursing in COPD?
Text:
The role of nursing in COPD is fundamental in aspects 
such as health education, and for the implantation of healthy 
habits, with the aim to improving/maintaining the patient’s 
quality of life [1, 23]. Education and support should also be 
aimed to family and caregivers.
Nursing is directly responsible, among others, of the fol-
lowing activities:
1.- Revise treatment to clarify doubts and avoid mistakes.
2.- Revise inhalation technique.
3.- Training in the handling of inhalers, inhalation chambers, 
rescue inhalers and nebulizers.
4.- Evaluate change of inhalers.
5.- Check the correct use of chronic home oxygen, both fixed 
and portable, in terms of use, hours, liters, mode. 
6.- Resolve doubts about non-invasive mechanical ventilation 
(NIV).
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There is a disproportion between the impact of COPD on 
public health and its presence in the general media. If we as-
sess La Vanguardia, over a period of two years as a case study 
(October 2016-September 2018), we observe that COPD has 
been cited in 14 articles, in one of which it has appeared in 
the headline (“An Everest for patients with COPD”, by Rosa M. 
Bosch, 6/4/2017). If we extend the sample to chronic bronchi-
tis and emphysema, it has been cited in a total of 18 articles. 
Although it is the third cause of death in the world according 
to the WHO, it is not the third disease with more presence in 
La Vanguardia.
To understand the reasons of this discrepancy, it is instruc-
tive to look at the coverage of other diseases with the greatest 
mortality impact: ischemic heart disease (9.4 million deaths in 
2016; cited in 131 articles; 28 headlines); stroke (5.8 million; 
101; 18); cancers (9.6 million; 584; 198); Alzheimer’s and other 
dementias (1.9; 122; 44); diabetes (1.6 million; 148; 17); di-
arrhoeal diseases (1.4 million; 33; 4); tuberculosis (1.3 million; 
71; 8); AIDS (970,000; 201; 63); malaria (470,000; 51; 11) [82]. 
These data show that there is no direct linear relationship be-
tween the epidemiological impact of a disease in terms of mor-
tality, and its presence in the media. Should we analyze those 
diseases not with the highest mortality, but the most disabling 
ones, such as depression or chronic back pain, a similar pattern 
emerges.
In order to understand the criteria on which a disease has 
more or less presence in the media, it is convenient to identify 
commonalities with those conditions most frequently reported 
(cancer, AIDS) and differences with those that are less covered 
(COPD, diarrheal diseases). This analysis reveals different varia-
bles with different relative weights. The two variables that have 
more weight are, on the one hand, the appearance of novel and 
relevant medical information associated with the disease and, 
on the other hand, the fact that a disease is associated with 
well-known public people.
Cancer and AIDS are examples of diseases that meet both 
requirements. At the other extreme, diarrheal diseases and 
COPD do not meet either of the two for the Spanish media.
All of the above diseases have a World Day on the cal-
endar, indicating that the variability in information cover-
age between them does not depend on having a World Day 
or not. 
An additional handicap of COPD is in its name, which is 
unfamiliar to large sections of the population. A similar hand-
icap has affected in recent decades stroke, which displaced 
terms that are better known among the population, such as 
embolism or apoplexy. In the same way that stroke has be-
come an everyday word, it is to be hoped that COPD will also 
do so in the future.
Conclusion:
There is no direct relationship between the frequency 
of a disease as a cause of death, and its media coverage. 
The diseases most frequently cited in media are those 
in which either the most “novel” medical information is 
girls already outnumber boys in tobacco use. In spite of this, 
COPD is still considered a disease that mainly affects men, 
which constitutes a diagnostic bias that contributes to the 
greater under-diagnosis in women in Spain [66, 67].
Female smokers are more susceptible than male to the 
harmful effects of tobacco, due to genetic, anatomical, and 
hormonal factors, and develop more severe and earlier-onset 
forms of COPD [68-70]. 
In published studies, women refer a greater degree of 
dyspnea than men for the same degree of airflow obstruction, 
and lower tobacco exposure [71, 72]. However, women present 
comparatively lower sputum production than men, which may 
be influenced by social factors [73]. Nutritional status, a fun-
damental clinical parameter to be evaluated in patients with 
COPD due to its potential as a prognostic predictor, seems to 
be altered more frequently in women [74, 75], who also pres-
ent more COPD exacerbations than men [76, 77], although 
with lower rates of re-hospitalization and better survival[78].
Regarding comorbidities, or diseases that are associated with 
COPD throughout its progression and interfere with the health 
status and prognosis of these patients, their expression is also dif-
ferent by sex. Data from the ECLIPSE study Agusti,[79], indicate 
that cardiovascular diseases are less prevalent in women with 
COPD, while disorders of the affective sphere are more frequent 
than in men. The presence of anxiety and depression in COPD-af-
fected women has an important impact on the disease, both be-
cause of its influence on symptom control and quality of life, and 
because of its relationship with prognosis, since it is associated 
with a greater risk of exacerbation, longer hospital stays, persis-
tence of tobacco consumption, less physical activity, greater mor-
tality and, possibly, less adherence to treatment [73]. Osteoporosis, 
with a prevalence close to 35%, also predominantly affects wom-
en, especially in post-menopause, and correlates with more severe 
forms of COPD and a low nutritional status [78].
In terms of treatment, published studies show that wom-
en tend to stop smoking less frequently, and that their success 
rate in long-term smoking cessation is lower than that of men 
[80, 81]. Finally, in home oxygen therapy or respiratory reha-
bilitation, few studies have been designed to evaluate their ef-
ficacy according to sex, so the available information is scarce 
and even contradictory. 
For all these reasons, COPD constitutes a growing health 
problem, especially in women. Priority should be given to im-
proving clinical suspicion and clinical characterization, to opti-
mize the therapeutic approach in female COPD patients.
Conclusion:
COPD is a growing health problem, especially in 
women. Priority should be given to improving clinical 
suspicion and clinical characterization to optimize the 
therapeutic approach in these patients.
Question 13. What does the media know and what 
does the specialized and non-specialized press publish on 
COPD? What does the “World COPD Day “ represent?
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- A strong political and institutional support, (i.e.: clear, public 
and transparent), with a guaranteed budget.
- Involvement of patients in decision-making (information and 
education) and in increasing home treatment.
- Improve coordination with the Autonomous Regions.
- Integrated and compatible clinical history.
- Comprehensive care process (PAI) with exacerbated COPD, 
avoiding re-entries [90].
- Respiratory rehabilitation, palliative care, control and treat-
ment.
- Effectiveness against smoking.
- Innovate, go to a results-based model (ICHOM). Behavioral 
economics [91], digitization, and big data.
Conclusion:
The current conditions in the approach to COPD of 
the National Health System favor “the perfect storm”. The 
ageing of the population and the increase of the neces-
sary resources require a serene and long-term planning 
that seems incompatible with the management of “the 
urgent”.
Question 15. COPD beyond tobacco. 
Text:
COPD has, traditionally, been considered as a self-inflict-
ed disease due to tobacco use [92]. Thus, in some genetically 
susceptible individuals, inhalation of tobacco smoke produces 
an excessive inflammatory response [93] which, in turn, causes 
accelerated loss of lung function with age [92]. Subsequently, 
it was recognized that inhalation of other particles and gases, 
such as those derived from the combustion of biomass for do-
mestic use, was also a significant COPD risk factor, especially in 
developing countries [94, 95]. And, even more recently, it has 
been proven that alterations in pulmonary development, dur-
ing pregnancy and after childbirth, due to genetic and/or en-
vironmental causes, are also an important risk factor for COPD 
[96]. In fact, approximately half of patients diagnosed with 
COPD in clinical practice, often in their fifth or sixth decade of 
life, already had evidence of poor lung development by the age 
of 30 [97]. It has also been shown that poor lung development 
is associated with poor development of other organs (cardio-
vascular, metabolic) resulting in a higher prevalence and in-
cidence of co-morbidities at early ages, and higher mortality 
[98]. The observation that COPD goes beyond tobacco opens 
new opportunities for its prevention and treatment [99].
Conclusion:
Tobacco use remains the main risk factor of COPD. 
However, it is not the only one. Inhalation of gases other 
than those produced by tobacco is also a cause of COPD. 
In addition, very recent research indicates that poor lung 
development before or after childbirth may also con-
tribute to the pathogenesis of COPD (and other chron-
ic diseases) in adulthood, opening new opportunities to 
produced, or in which celebrities are involved. Having a 
World Day is not a factor of relevance.
Question 14.- What are the current strategies for 
COPD? What are the alternative solutions to improve 
their quality and effectiveness?
Text:
The National Strategy Against COPD has had, so far, a pos-
itive impact. However, there is a lack of resources (human and 
economic), a lack of quality spirometries and proactive diag-
nosis, deficient computer systems, great variability in care, low 
adherence to Clinical Practice Guidelines, deficient training in 
self-care, deficient care coordination, and far too high rates of 
readmissions.
In relation to COPD, the National Health System (SNS) in 
Spain confronts an increase in chronicity, a greater demand for 
care, a growth in technological complexity and an increase in 
dependence, and the need for social health care. These are all 
important elements for a “perfect storm”. To them it must be 
added the deep economic and social crisis, and an unsustaina-
ble model of health and social protection. Should there be no 
reforms a crisis of the system is envisaged.
The most relevant factor is demographic ageing. The popu-
lation aged 65 years and older would account for 25.2% of the 
total in 2033 [83]. The coincidence in time of a formidable in-
crease in the population to be treated, aged and multi-morbid, 
consuming enormous health resources, in a context of health 
budgets with little annual variation and very tight (downwards) 
to changes of GDP is “the perfect storm” [84]. There is no ongo-
ing reform of the NHS, to achieve long-term sustainability and 
to avoid future recessions [85].
To overcome this storm, “we must be ready to reorganize 
the health system with new policies, plans, and programs, and 
be willing to convince decision-makers that only by acting on 
three pillars - patient-centered care, hospital efficiency, and 
carrying out interventions in the optimal (home) environment 
- can we avoid disaster” [84].
The Spanish NHS needs strategic management of future 
crises, identifying trends and anticipating solutions before it is 
too late [86]. If the urgent displaces the important, it prevents 
us from facing any long-term challenges. It is the “curse of 
short-termism” that takes away our time for reflection, with-
out the capacity to adapt and anticipate. Reforms and changes 
are delayed “sine die” [87].
We need quality information on the impacts of current de-
cisions and their alternatives, with appropriate measurement in-
struments and a multi-system thinking approach [88]. There are 
no simple solutions to complex problems. We obtain an enor-
mous amount of data which, if well analyzed and shared, should 
enable the implementation of public policies backed by objective 
data [89]. We should avoid unfounded or improvised policies 
that are never evaluated. Some alternatives might be:
- A more efficient, flexible, modern, professional and inde-
pendent organizational structure.
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In any case, the challenge for future GPCs is to develop evi-
dence-based recommendations, free from bias and useful to 
the clinician [105].
In Spain there is the Spanish COPD Guide (Gesepoc) led 
by the Spanish Society of Pneumology and Thoracic Surgery 
(SEPAR). It is conducted in collaboration with all the scientific 
societies involved in the care of COPD patients, plus patient as-
sociations. Its first edition was published in 2012, and its latest 
revision in 2017 [106]. It is a GPC that uses the GRADE system 
of evidence evaluation, and has had a progressive implemen-
tation, so that in 2016, 46% of the clinical charts of patients 
with COPD audited in Spain included the classification accord-
ing to the Gesepoc guide.
Conclusion:
Clinical Practice Guidelines offer a series of recom-
mendations based on scientific evidence. CPGs are not 
without methodological problems and difficulties, but 
compliance improves clinical outcomes and patients’ 
quality of life.
Question 17.- What is the CIBERES (Centro de Inves-
tigación Biomédica en Red en Enfermedades Respirato-
rias)? What has been the contribution of CIBERES to the 
management of COPD in Spain?
Text:
A few years ago, the Spanish Government decided to cre-
ate specific research institutes and created the CNIC (National 
Centre for Cardiological Research) or the CNIO (National Cen-
tre for Oncological Research) on the grounds of the “Carlos III 
Institute”. Each had a separate building, that was filled with 
researchers, and hired star directors with the aim of promoting 
research excellence in oncology and cardiology, two important 
pillars of a society’s health.
Over time, maintaining the building and that structure 
has a fixed cost, which limits the return on investment. Some 
twelve years ago, other models of research centers were cho-
sen, which are the CIBER (Centers for Biomedical Research 
Networks). In these CIBERs there are no buildings (networked 
centers), and what they do is to put in communication the ex-
isting teams and groups of excellence of each of the areas of 
knowledge. They are provided with a non-physical structure 
and are assigned a budget to manage it for the same purpose 
they had for the CNIC or the CNIO.
What do we gain from this? We gain that we no longer 
have permanent staff researching in a building, but we have 
the best of the country, working together in each of their 
specific areas, working cooperatively and avoiding the cost 
associated with the structure. Each Euro invested is much 
more efficient and generates much more knowledge. Another 
advantage is that the structure is not fixed and permanent, 
so that the groups that make up the CIBER do not have the 
right to remain indefinitely. After yearly evaluations, the 
“worse” of those are excluded, and other groups can apply 
and be included.
implement much earlier prophylactic and/or therapeutic 
measures.
Question 16.- What do Clinical Practice Guidelines 
contribute? How should the Guidelines of the future be?
Text:
Clinical practice guidelines (CPGs) aim to improve the 
quality of health care and reduce variability in the treatment 
of patients. CPGs make treatment recommendations based 
on available evidence and, when evidence is not available, 
based on expert opinion. In recent years GPCs have evolved 
towards a greater recognition of the imperative need for a 
systematic approach to evidence and a very rigorous manu-
facturing process to ensure that only accurate and appropri-
ate recommendations are issued. The use of methodologies 
such as GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) allows for the elaboration of 
recommendations that are robust and as free of bias as pos-
sible [100]. However, the use of this methodology implies a 
very high cost in time and money and limits the application 
of the guide to a series of previously defined assumptions in 
the form of PICO questions (patients, intervention, compar-
ison, outcomes). This fact, together with the difficult inter-
pretation by clinicians of the results of the GRADE system, 
has implied that various scientific societies have tried to find 
ways to improve and/or simplify the elaboration of GPCs 
without losing reliability. For example, the American Col-
lege of Chest Physicians has initiated what they call a hybrid 
process, that includes recommendations based on evidence 
according to the GRADE system; and when the evidence is 
insufficient, they combine it with a Delphi process to reach 
a consensus that results in reliable positioning [101]. To this 
end, they have developed a structured process that includes 
a systematic review of the literature and very strict rules on 
expert participation and voting [101].
The American Thoracic Society (ATS) is developing the 
CORE (Convergence of Opinion on Recommendations and Ev-
idence) process, which aims to discriminate at the beginning 
of the development of the GPC those recommendations that 
should be developed through a systematic review of the lit-
erature and those that can be based on expert opinion. The 
CORE is a type of modified Delphi, which in a study showed 
that it offers very similar results to the GRADE process in many 
recommendations, which would in many cases allow recom-
mendations to be formulated with great savings in time and 
resources [102].
The European Respiratory Society (ERS) has initiated 
a mixed process in the development of GPCs that includes 
the formulation of PICO questions, and a systematic review 
with recommendations according to the GRADE system, but 
together with non-PICO questions in aspects where there is 
no evidence and that will generate recommendations based 
always on the EtD (Evidence to Decision) process [103] to ex-
plain in a clear and transparent way, what type of informa-
tion has been used to establish the recommendation [104]. 
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BERES, not equally, but according to the annual evaluation of 
each of the groups.
To evaluate the scientific contribution of CIBERES since 
2008, we have carried out a search in PUBMED according to 
the following criteria: CIBERES (Affiliation) + Spain (Affiliation) 
+ Year of Publication +/- COPD OR EPOC. With these crite-
ria, we offer the evolution, in number of global publications 
and particularly referring to COPD produced by the network. 
The graphs (figures 1 and 2) are worth more than a thousand 
words and demonstrate the spectacular the impact of the 
At CIBERES there are, nowadays, 34 research groups with 
different areas of interest in respiratory diseases. They repre-
sent the excellence of research in respiratory medicine in our 
country. That network has a scientific director, a management 
support structure, a management committee, and some inter-
nal and external scientific advisory committees, along with a 
minimal management structure that is physically in the Carlos 
III Institute in Madrid.
An annual budget of around 2.7 million Euros is received, 
and that money is distributed among groups that make up CI-
Figure 1  Progress of the overall scientific production of CIBERES followed through 
PubMed.
Figure 2  Progress of the scientific production in COPD, of CIBERES (number of 
publications indexed per year)
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smokers, men, and those older than 65 years of age is 
changing rapidly. In the United States, more women than 
men die with COPD. The situation in 2050 is difficult to 
predict and will depend not only on factors such as trends 
in smoking, but also on changes in poverty and longevity.
Question 19.- What are the main objectives of pa-
tient associations? What should they change? 
Text:
The WHO in 2008 wrote a report which showed that pa-
tient participation in their own processes can improve health 
outcomes, patient satisfaction, and even be economically ben-
eficial [109]. In order to achieve these objectives, patients must 
join forces and associate. Patient Associations can play a fun-
damental role, being an important intersection between Public 
Health, health systems, health administrations, professionals, 
and society.
From a critical point of view, there are more than 6,000 
patient associations in Spain; probably there are too many. 
They have very different levels of organization, development 
and action, and although there is a progressive improvement, 
it can be said that, in general, there is a lack of training, struc-
ture and leadership. There are, however, some well-structured 
and consolidated associations and federations.
Patient Associations can play a fundamental role, being 
a relevant intersection between Public Health, health systems, 
health administrations, professionals and society.
With a surge of patient associations [110, 111], the health 
system appears as a complex entity, with national, regional 
and local levels and with communication problems in all of 
them. There are problems of access to innovation, and inequal-
ities in access to benefits, especially new therapies.
In our opinion, the main weaknesses of patient associa-
tions in Spain are:
- Scarce number of associates. Only 3% of patients belong to 
an association.
- Scarce economic resources. Subsidies are very scarce, and it 
is difficult to find resources from other sources.
- Physical limitations caused mainly by the disease or the re-
covery process of the people involved in its operation.
- Limitations of administrative knowledge. It is almost impos-
sible to have associates, with time and useful professions, 
to deal with all administrative, legal and management is-
sues, often complex and requiring significant dedication 
and qualification.
In Spain, FENAER (Federación Española de Asociaciones de 
Pacientes Alérgicos y con Enfermedades Respiratorias) [112] 
tries to “be the voice of patients” with allergies, asthma, COPD 
and other risk factors, and participates actively in decisions af-
fecting health.
Conclusion:
Patient associations in Spain are probably exces-
money invested in this research group in top-quality scientif-
ic production. We have not included the formative impact on 
new researchers, nor do we have any record of the impact all 
this has had on improving people’s quality of life, but we do 
not doubt this relationship.
Conclusion:
CIBERES is a state organization for research in res-
piratory medicine. It brings together 34 multidisciplinary 
research groups. CIBERES, with 10 years in operation to 
date, has contributed to a better knowledge and manage-
ment of COPD, with an extraordinary scientific produc-
tion, and the training of countless Spanish researchers in 
this field.
Question 18.- What is the current paradigm of 
COPD? Could we speculate on the future of COPD for the 
year 2050? 
Text:
Along the XXth Century, COPD was a disease associated 
with the triad of man, smoker, and older than 65 years. The cur-
rent paradigm is changing and is that of a chronic disease asso-
ciated with aging and smoking, requiring comprehensive treat-
ment by specialists in Pneumology, but also Nursing, Primary 
Care and Internal Medicine. COPD is becoming feminized, and in 
the United States more women than men die with this disease. 
In Spain, it is estimated that in 2017 more than 28,000 people 
died with COPD, that is 17,300 men and 11,400 women. In ad-
dition, COPD is detected earlier, and patients live longer, so that 
the age of diagnosis, which before was usually between 65 and 
69 years, now has a much wider range [11]. In the medium-term 
future, say in 2050, the burden of COPD could be reduced by re-
ducing environmental pollution and controlling smoking (106). 
Tobacco use rates remain high in many developing countries 
and some developed countries, and indoor and outdoor pol-
lution and occupational exposures are still serious problems in 
many countries. But the greatest current determinant of COPD 
is age. As life expectancy increases, and the ageing population 
increases, the burden of COPD can be expected to increase.
It is likely that promoting the development of better med-
ical care, using newer and more effective drugs for COPD, and 
their increased adherence, will reduce disease-related mortal-
ity; thus, new cases of COPD will exceed the number of deaths 
caused by it, resulting in an increased burden of COPD.
Finally, it should be noted that the prevalence of COPD 
or airflow obstruction is more frequent in areas with a high 
prevalence of cigarette use. However, although it may seem 
a population paradox, COPD mortality is more closely related 
to the prevalence of low forced vital capacity (FVC) which, in 
turn, is more associated with poverty than with smoking [107, 
108]. In 2050 there will be more people dying with COPD than 
from COPD; but since 2015, it is the third cause of death in the 
world, and the fourth in Spain.
Conclusion:
The current paradigm of COPD as a disease involving 
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Conclusion:
COPD is one of the main objectives of the nation-
al and regional health plans in Spain. The plans include 
several strategic lines, one of which is the promotion and 
stimulation of research. On the other hand, the public 
health administration also assesses the added therapeu-
tic value of innovations, to ensure equitable access within 
the national health system.
Question 21.- What reflections from the ethics per-
spective do we propose?
Text:
COPD, as its name indicates, has chronicity as one of 
its main characteristics. The distinction between acute and 
chronic processes is as old as Western medicine itself. It is 
already found in the Hippocratic writings, those with which 
our medicine was born. On those writings, one of the main 
characteristics of chronic diseases, was the consideration that 
environmental factors had evident influence on them. On the 
contrary, acute diseases were not only characterized by their 
sudden and rapid appearance, but also because in them it was 
not possible, or at least it was not for the ancient doctors, to 
establish a close correlation between life habits and the gene-
sis of the disease, something that was verifiable in the case of 
chronic diseases. In these, in fact, prolonged disorders in the 
diet or in any other aspect of life have an obvious nosogenic 
effect. This is the case of excessive eating or sedentarism in the 
development of diseases such as obesity or diabetes.
The case of COPD is particularly significant. Like most 
respiratory diseases, it is closely related to substances that 
are introduced into the lungs when breathing. In the specific 
case of COPD, with those coming from the use of tobacco. In 
other lung diseases, these are other products present in the 
atmosphere. This explains why many lung diseases are rela-
tively modern and are linked to industrial development, the 
increase in fossil fuels, air pollution in cities, etc. The natural 
history of COPD has been associated with the introduction of 
tobacco in the habits of Western culture, after the discovery 
of America. The description of tobacco smoking given by the 
doctor and botanist Francisco Hernández in the notes of his 
scientific expedition to New Spain (1571-1577) is classic: “the 
sense of sorrows and works is blunted, and it completely in-
vades the spirit as a rest for all faculties, which could be called 
an almost inebriety’”. [118]. This made its use spread rapidly, 
although the greatest increase began in the late nineteenth 
century, because of mechanization and industrialization of 
both harvesting and marketing. In fact, mass consumption of 
tobacco has taken place in the twentieth century. The pioneer-
ing studies by Richard Doll and Bradford Hill [119-121] point-
ed out to the carcinogenic effect of tobacco smoking, that was 
verified even in the non-smoking wives of male smokers [122]. 
From then on, its worldwide consumption began to decrease.
The correlation between tobacco use and lung cancer is 
now evident, but not so of tobacco use and other lung diseas-
sive in number and deficient in number of associates, 
and need stronger structures, better funding and more 
knowledge of the health administration. Such changes 
would help them to exert the necessary impact that is 
expected from them.
Question 20.- What is necessary to prepare and 
change the future of COPD in Spain? The view of health-
care administrators.
Text:
The National Health System (SNS) plans in Spain estab-
lishes the objectives and programming of activities of the pub-
lic health administration. One of the objectives of the Quality 
Plan of the SNS is to improve care for the most prevalent dis-
eases with the highest care, family, social and economic bur-
den, including COPD [113] among them. It was in this context 
that the National SNS COPD Strategy was developed, which 
was divided into six strategic lines of action, one of which was 
research [114]. The general objectives of this strategic line 
were to promote epidemiological, basic, clinical and transla-
tional research, in aspects of prevention and comprehensive 
COPD care. The specific objectives were to establish priority 
lines of research, to promote, through their inclusion in calls 
for research projects, priority interdisciplinary lines of research 
in COPD, to implement measures to promote the creation of 
accredited networks of research centers and groups of excel-
lence in COPD, and to promote research in primary care on 
COPD care.
The autonomous communities in Spain have also devel-
oped health plans. For example, in Catalonia the 2016-2020 
Health Plan has selected nine priority areas of prevalent 
chronic health problems, one of which is respiratory diseases 
[115]. In addition, the Health Plan has also prioritized research 
and innovation through the development of the Strategic Plan 
for Research and Innovation in Health [116]. The thematic pri-
orities of this Strategic Research Plan are aligned with those 
established in the Catalan Health Plan, and respiratory diseases 
have been included as one of the preferred topics.
On the other hand, there is also private promotional re-
search that is developing new products based on the discovery 
of new therapeutic targets [117]. In approaching the incorpo-
ration of pharmacological research, it is necessary to antici-
pate and plan for access to future innovation. In this sense, 
an axis of work of the public health administration has been 
the creation of a “radar” or “horizon scanning” system of phar-
macological innovation, to anticipate and plan access to it in 
the public health system [115]. Furthermore, it is necessary to 
evaluate the pharmacological innovations that are marketed in 
order to determine the added therapeutic value that they pro-
vide and to guarantee equity in access to these innovations in 
the field of public health, in accordance with the principles of 
effectiveness, safety, efficiency and sustainability of the pub-
lic health system, as well as the conditions of use, access and 
provision.
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